Facing public skepticism about rushed COVID-19 vaccines, U.S. health officials are planning extra scrutiny of the first people vaccinated when shots become available — an added safety layer experts call vital.
The chief executive of Pfizer said on Friday that the company would not apply for emergency authorization of its coronavirus vaccine before the third week of November, ruling out President Trump’s assertion that a vaccine would be ready before Election Day on Nov. 3.
U.S. regulators Wednesday approved the first drug for the treatment of Ebola.
The Food and Drug Administration OK’d the drug developed by Regeneron Pharmaceuticals for treating adults and children. It was tested during an outbreak in Congo that killed nearly 2,300 people before it ended in June.
....Clearly, the pandemic has not ended. So far some 215,000 Americans have lost their lives to the coronavirus, and reliable estimates suggest that the number could reach 400,000. Health experts agree that, with stronger leadership, the death toll would have been far lower.
Recent Comments